Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.
General Outlook
In simple terms, Applied Molecular Transport Inc. has 41.849 M shares that people are buying and selling right now.
Return on Investments
The company's asset efficiency, represented by a robust -3.655% return, is a testament to Applied Molecular Transport Inc.'s adeptness in optimizing resource deployment. Applied Molecular Transport Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -2.186%. Furthermore, the proficiency of Applied Molecular Transport Inc. in capital utilization is underscored by a remarkable -4.712% return on capital employed.
Stock Prices
Applied Molecular Transport Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.2059, while its low point bottomed out at $0.185. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Applied Molecular Transport Inc.'s stock market.
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”